Kornimate/medical-research-clean huggingface dataset:
a novel diet approach to combat gestational diabetes

Conditions: Diabetes, Gestational

Summary: there is an urgent need to implement novel diet approaches to combat the increasing rates of gestational diabetes mellitus (gdm). the primary aim of this study is to establish the feasibility of time-restricted eating in pregnancy, to prepare for future larger controlled trials in this research project to determine the efficacy of time-restricted eating in women at risk of gdm. expectations: 1. women who have an increased risk of gdm will be able to adhere to time reduced eating during pregnancy. 2. time reduced eating will improve short-term glycemic control in pregnancy.


Eligibility criteria:
inclusion criteria: * carrying one singleton live foetus * in pregnancy week 12-30 * having at least one risk factor for gestational diabetes mellitus (gdm) according to norwegian guidelines for gdm screening: pre-pregnancy bmi \> 25 kg/m2, gdm in previous pregnancy, primiparae aged \> 25 years, first degree relative with diabetes mellitus, asian or african ethnicity, previous delivery of new-born \> 4.5 kg * understand written and spoken norwegian language exclusion criteria: * habitual eating window \< 12 hours

Keywords: exercise therapy diet prevention and control
evaluation of clinical performance of self-adhering flowable composite vs conventional flowable composite in cervical carious lesions

Conditions: Dental Caries

Summary: this clinical trial will be conducted to compare the clinical performance of a new self-adhering flowable composite in restoring cls compared to conventional flowable composite in geriatric patients over 12 months.

recently, self-adhesive flowable composites (safcs) have been introduced as a new class of restorative material in adhesive dentistry. today, there are only two available products in the market for clinical use: vertise flow and fusio liquid dentin. self-adhering flowable composite was introduced to address the time-consuming procedure used with traditional materials their resin matrix contains acidic functional adhesive monomers mediating bonding with dental hard tissues and, therefore, separate etching and additional bonding are not required. safcs have been mainly advertised for the restoration of small class i, class iii and v cavities, for cavity lining, and for use as a pit and fissure sealant. self-adhering flowable composite combines the merits of both adhesive and restorative material technologies in one product, bringing novel horizons to restorative techniques, as it is a direct composite resin restorative material that has an adhesive resin together with a flowable composite resin. it is based on the bonding technology that uses glycerophosphate dimethacrylate(gpdm)to etch enamel and dentin, and hydroxyethyl methacrylate (hema) to enhance wetting and penetration by resin into dentin. this resin bonds chemically between the phosphate groups of a gpdm monomer and the hydroxyapatite of tooth structure and, also, micromechanically between the polymerized monomers of the self-adhering flowable composite resin and the collagen fibers and smear layer of dentin.

Eligibility criteria:
inclusion criteria: * cervical class v carious lesions in anterior and premolars teeth. * age above 60 years. * males and females. exclusion criteria: * • patient less than 60 years with disabilities, systemic disease, severe medical conditions, rampant caries, and xerostomia. * in addition, teeth with potential prosthodontics restoration and nonvital or endodontically treated teeth.
treatment of depressed chronic obstructive pulmonary disease patients

Conditions: Pulmonary Disease, Chronic Obstructive; Major Depression

Summary: approximately 20% of patients with chronic obstructive pulmonary disease (copd) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity. this study investigates the effectiveness of a care management intervention aimed at facilitating adherence to a treatment algorithm based on the agency for health care policy and research (ahcpr) guidelines. the investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability at a 28-week follow-up period.


Eligibility criteria:
inclusion criteria: * chronic obstructive pulmonary disease by american thoracic society criteria * major depression by dsm-iv criteria * 17-item hamilton score \>14 * english speaking exclusion criteria: * inability to give informed consent * minimental score \<24 * aphasia * nursing home placement after discharge
prediction of chronic pain in cardiac surgery: evaluation by algocartography predict-algocarte

Conditions: Sternotomy Closure,open Heart Surgery; Cardiac Surgery; Chronic Pain Post-Procedural

Summary: sternotomy results in chronic postoperative pain in 30-55% of subjects. few studies have been published on chronic pain in cardiac surgery, but there appears to be a relationship between the area of peri-scar hyperalgesia, which is indicative of postoperative hyperalgesia, and the occurrence of persistent pain 6 months after surgery. the aim of this study was therefore to assess whether the area of the postoperative hyperalgesia zone predicts chronic pain at 3 months post-surgery in cardiac surgery. to define the area of hyperalgesia at day 2, pain mapping (algocartography) will be performed in patients who have had a sternotomy in cardiac surgery, together with pain assessment using the simple digital pain scale. von frey filaments of different sizes will be used for mapping. at day 90, additional quality-of-life questionnaires will be carried out to check whether chronic pain is still present. a simple numerical scale (ens) assessment at rest and during activity, and a record of pain-relieving treatments related to the surgery will also be carried out during this call. the investigators hypothesize that the area of the zone of hyperalgesia assessed at day 2 predicts the occurrence of chronic pain at 3 months.


Eligibility criteria:
inclusion criteria: * scheduled surgery * conventional cardiac surgery by sternotomy: valve repair or replacement, coronary, thoracic aortic or combined surgery * age over 18 * no opposition from patient * patient affiliated to a social security exclusion criteria: * emergency surgery * patient refusal * redux surgery * patients under guardianship * history of drug addiction * preoperative opioid treatment * morbid obesity (body mass index \>30kg/m2) * pregnant or breast-feeding women * patients taking part in another clinical study likely to interfere with the results of the present study.

Keywords: chronic pain prediction cardiac surgery algocartography area of hyperalgesia
a study to explore treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with myelofibrosis through chart review

Conditions: Myelofibrosis

Summary: myelofibrosis (mf) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. it is one of a group of cancers known as myeloproliferative neoplasms (mpns) in which bone marrow cells that produce blood cells develop and function abnormally. this study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with myelofibrosis. data from approximately 1000 participants will be collected. no participants will be enrolled in this study. participants' charts will be reviewed. no drug will be administered as a part of this study. the duration of the observation period is up to 156 weeks. there is no additional burden for participants in this trial. all visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.


Eligibility criteria:
inclusion criteria: * treated for myelofibrosis (mf) \[primary myelofibrosis (pmf) and secondary myelofibrosis (smf)\]. * must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 december 2021. exclusion criteria: - having received mf treatment in a clinical trial setting.

Keywords: myelofibrosis cancer
therapeutic hypothermia for severe traumatic brain injury in japan

Conditions: Brain Injuries, Traumatic

Summary: the purpose of this trial is to determine if mild hypothermia therapy, for severe head trauma patients, improves neurological outcome.

mild hypothermia therapy shows protective effects for damaged brains of animals and post cardiac arrest patients. however, clifton et al. reported that mild hypothermia has no protective effect for severe head trauma but has a risk of complications. in this study, all the participants must be treated with continuous monitoring of cardiac output and jugular venous oxygen saturation to get optimal physiological conditions. adequate anesthesia such as neuroleptanesthesia is essential to maintain organ function and tissue microcirculation. participants are randomly assigned to two groups of mild hypothermia (32.0 - 34.0 degree celsius) and anti-hyperthermia (35.5 - 37.0 c). the body temperature must be kept for at least 72 hours. hypothermia must be induced within 6 hours after traumatic brain injury. glasgow outcome score at 6 months after injury and the total medical expenses of the two groups will be evaluated.

Eligibility criteria:
inclusion criteria: * traumatic brain injury; glasgow coma score 4-8 (motor 1-5). * hypothermia or anti-hyperthermia must be induced within 6 hours after injury. exclusion criteria: * systolic blood pressure \< 90mmhg (after resuscitation) * thrombocytopenia (platelets \[plt\] \< 50,000/mm3) * pregnancy * preexisting medical conditions of severe hepatic dysfunction, heart failure or any other severe organ failure * deep drunkenness

Keywords: hypothermia, induced traumatic brain injuries anesthesia neuro-intensive care neurochemistry
structural and functional imaging and cognitive functions in ovarian cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer

Summary: the purpose of this study is to learn about possible changes in brain anatomy and function, and in thinking abilities, such as memory skills, in patients with ovarian cancer who receive treatment with chemotherapy. cancer patients treated with chemotherapy may experience changes in thinking abilities, and these may interfere with quality of life. most of the research to date has involved patients with breast cancer, and there are no studies in women with ovarian cancer looking at at treatment-related changes in brain anatomy and function.


Eligibility criteria:
inclusion criteria: * diagnosed with stage i-iv ovarian, peritoneal or fallopian tube cancer * completed first-line taxane and platinum-based chemotherapy 1-4 months prior to being enrolled in the study (can be on bevacizumab maintenance) * in remission of their disease at the time of enrollment between 21 and 70 years of age * fluent in english * in the judgment of the consenting professional, have capacity to give consent healthy control inclusion criteria: * no diagnosis of cancer except basal cell carcinoma * between 21 and 70 years of age * fluent in english * has a mini-mental state exam (mmse) score of 26 or higher * in the judgment of the consenting professional, have capacity to give consent exclusion criteria: * active or recurrent disease, or diagnosis of another cancer (except basal cell carcinoma) as per medical records at the time of enrollment * exposure to chemotherapy or radiation therapy for any medical condition unrelated to ovarian cancer * on hormonal therapy at the time of enrollment * neurological disorder or moderate to severe head trauma (loss of consciousness \> 60 min) * neurodegenerative disorders such as alzheimer's disease, parkinson's disease, multiple sclerosis, etc. * self-reported axis i psychiatric disorder (dsm-iv), major affective disorder (untreated), bipolar disorder, schizophrenia * unable to complete cognitive tests * with standard contraindications to mri examinations healthy control exclusion criteria: * exposure to chemotherapy or radiation therapy for any medical condition * on hormone replacement therapy at the time of enrollment * neurological disorder or moderate to severe head trauma (loss of consciousness \> 60 min) * neurodegenerative disorders such as alzheimer's disease, parkinson's disease, multiple sclerosis, etc.

Keywords: fallopian tube ovary peritoneum quality of life structural mri functional mri neuropsychological assessment 12-075
development of the mdasi-spine tumor module

Conditions: Spinal Cord Tumor

Summary: the goal of this research study is to learn the severity of certain symptoms in patients with tumors of the spine or spinal cord. researchers also want to learn if the m. d. anderson symptom inventory-spine is a good way to rate these symptoms. primary objective: 1. to evaluate the psychometric properties of the mdasi-spine in patients with tumors involving the spine or spinal cord. secondary objective: 1. to describe the severity of commonly occurring symptoms experienced by persons with spine tumors.

if you agree to take part in this study, you will complete the m. d. anderson symptom inventory-spine tumor module survey. this survey will ask you to rate the severity of certain symptoms you may have had in the last 24 hours on a scale of 0 (not present) to 10 (the most severe you can imagine). you will also be asked to rate how your symptoms get in the way of your daily activities using the same 0 to 10 scale. this survey should take about 10-15 minutes to complete. information regarding your clinical history (tumor type, location, treatment, and other medications) and demographic information (age, gender, ethnicity, religion, educational level, and marital status) will also be collected. this information will be used to evaluation whether there is an association between symptom severity and these factors. once you have completed the survey, your participation on this study will be over. this is an investigational study. up to 128 patients will take part in this study. all will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: 1. diagnosis of a tumor involving the spinal cord (intramedullary or extramedullary) 2. age \> or = to 18 years of age 3. ability to speak and read english. non-english speaking subjects will be included in future studies, once the final instrument has been developed. exclusion criteria: 1. patients \< 18 years of age 2. evidence of gross cognitive dysfunction limiting memory or ability to complete a self-report questionnaire as determined by evaluation of physician or mid-level provider.

Keywords: spinal cord tumor intramedullary spinal cord tumor extramedullary spinal cord tumor symptoms survey
analgesia after total hip arthroplasty: peri-articular injection versus epidural patient controlled analgesia (pca)

Conditions: Osteoarthritis

Summary: the best way to provide analgesia after total hip arthroplasty is hotly debated. there are two protocols in use at hospital for special surgery(hss). both protocols have their proponents, but there are limited data for making an informed choice of protocols. for total hip arthroplasty at hss, epidural analgesia is used most frequently as it reduces pain with physical therapy. however, epidural analgesia can be associated with nausea, pruritis, dizziness, and orthostatic hypotension. these side-effects can slow physical therapy and may prolong the time until the patient is ready for discharge. some surgeons at hss have decided to use a different analgesic protocol, based on a peri-articular injection. this protocol avoids epidural analgesia and systemic opioids. however, patients are given oral opioids as part of a multimodal pain therapy. the investigators propose to compare peri-articular injection to epidural patient controlled analgesia (epidural pca). the investigators will enroll 90 total patients (45 per study arm). the enrollment period will be approximately one year and the duration of the follow-up with study patients will be three months following their procedure.


Eligibility criteria:
inclusion criteria: * patients with osteoarthritis scheduled for primary total hip arthroplasty with a participating surgeon * age 50 to 80 years old * planned use of regional anesthesia * ability to follow study protocol exclusion criteria: * patients younger than 50 years old and older than 80 * patients intending to receive general anesthesia * allergy or intolerance to one of the study medications * patients with an asa of iv * patients with insulin-dependent diabetes * patients with hepatic (liver) failure * patients with chronic renal (kidney) failure * chronic opioid use (taking opioids for longer than 3 months) * patients with any prior major ipsilateral hip surgery * allergy to any of the medications (or adhesives) involved in the protocol

Keywords: total hip arthroplasty total hip replacement
gaba-glutamate interactions and psychosis

Conditions: Cognitive Dysfunction

Summary: this study investigates the interactions between nmda (n-methyl-d-aspartic acid) antagonism and gaba (gamma-aminobutyric acid) system as it relates to cognitive function assessed by erps (event-related potentials) in healthy volunteers.


Eligibility criteria:
inclusion criteria: * ages of 21-45 years from all ethnic backgrounds. * male or female. * written informed consent. exclusion criteria: * dsm-iv diagnosis for a psychotic, depressive or anxiety disorder. * a history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic abnormality, seizure disorder. unstable medical condition based on ekg, vital signs, physical examination and laboratory work-up (cbc with differential, sma-7, lfts, tfts, ua, utox). * history of abnormal eeg. * history of severe allergies or multiple adverse drug reactions. * any medication that could interfere with either the safety of the study and/or the outcome measures. * any other conditions which in the opinion of the investigator would preclude participation in the study. * history of major psychiatric disorder in first degree relatives. * current substance abuse/dependency determined by urine toxicology. * treatment with medications with cns effects. * treatment with benzodiazepines within one week prior to testing. * current treatment with medications with psychotropic effects. * education \< 10th grade. * iq \< 70, mr. * non-english speaking.

Keywords: gaba glutamate nmda p300 mmn
therapeutic hypothermia after cardiac arrest in non shockable rhythm

Conditions: Cardiac Arrest

Summary: cardiac arrest is at present a major cause of mortality as well as a cause of disability for the surviving victims.in europe, every year counts as 300,000 cardiac arrests responsible for 250,000 deaths. thus, less than 20 % of patients discharged home with impaired quality of life associated with symptoms of tiredness, stress, anxiety. the prognosis is related to the initial cardiac rhythm present during the initiation of resuscitation. recent progress in the improvement of mortality and neurological outcome has been achieved over the last decade thanks to the systematic implementation of a period of targeted temperature control between 32 and 34 ° c in patients who benefited from the realization of at least one electrical external shock. there are theoretical and clinical arguments to think that achieving the same way a period of targeted temperature control between 32 and 34 ° c in patients treated for cardiac arrest with a non- shockable rhythm on arrival can also benefit from this procedure. however other arguments are against this hypothesis including an increase in the risk of infection , worsening of the patient's hemodynamic status with no benefit to him. to answer this question, we conduce a randomized multicenter study testing the potential improvement of neurological outcome through this procedure targeted temperature control between 32.5 and 33.5 ° c in these patients.


Eligibility criteria:
inclusion criteria: * cardiac arrest in non shockable rhythm * glasgow score ≤ 8 exclusion criteria: * no flow \> 10 min * low flow \> 60 min * major hemodynamic instability * delay between cardiac arrest and inclusion \> 300 min * cirrhosis child c * age \< 18 years * pregnant women * patient with no liberty * lack of informed consent * prior inclusion in a research protocol involving cardiac arrest with draw, and whose primary endpoint focuses on the evaluation of a neurological score day 90

Keywords: therapeutic hypothermia targeted controlled temperature cardiac arrest non shockable rhythm successful resuscitation
haic combined withzoledronic acid for the prevention of bone metastases in advanced hcc

Conditions: Hepatocellular Carcinoma

Summary: zoledronic acid was initially used for bone metastases in various malignancies. however, it is unknown whether hepatic arterial infusion chemotherapy combined with zoledronic acid can improve overall survival of unresectable hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * the diagnosis of hcc was based on the diagnostic criteria for hcc used by the european association for the study of the liver (easl) * patients must have at least one tumor lesion that can be accurately measured according to easl criteria. * unresectable hcc. for bclc c hcc, sorafenib/lenvatinib or pd-1/l1 antibody was allowed. * eastern cooperative oncology group performance status of 0 to 2 * with no previous treatment * no cirrhosis or cirrhotic status of child-pugh class a only * not amendable to surgical resection ,local ablative therapy and any other cured treatment. * the following laboratory parameters: * platelet count ≥ 75,000/μl * hemoglobin ≥ 8.5 g/dl * total bilirubin ≤ 30mmol/l * serum albumin ≥ 30 g/l * asl and ast ≤ 5 x upper limit of normal * serum creatinine ≤ 1.5 x upper limit of normal * inr ≤ 1.5 or pt/aptt within normal limits * absolute neutrophil count (anc) \>1,500/mm3 * ability to understand the protocol and to agree to and sign a written informed consent document exclusion criteria: * evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy * known history of hiv * history of organ allograft * known or suspected allergy to the investigational agents or any agent given in association with this trial. * cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * evidence of bleeding diathesis. * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * known central nervous system tumors including metastatic brain disease

Keywords: hepatocellular carcinoma zoledronic acid hepatic arterial infusion chemotherapy